Diclofenac Topical vs PEA
A side-by-side research comparison of Diclofenac Topical and PEA across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Diclofenac Topical | PEA |
|---|---|---|
| Full name | Diclofenac Sodium Topical Gel (Voltaren) | Palmitoylethanolamide |
| Category | Pain & Inflammation | Pain & Inflammation |
| Status | FDA Approved (OTC) | Dietary supplement (medical food in EU) |
| Mechanism | Inhibits cyclooxygenase-1 and -2 (COX-1/2) locally in tissue, reducing prostaglandin E2 synthesis at the inflammation site. Topical delivery achieves therapeutic tissue concentrations with plasma levels <5% of oral dosing. | Activates PPARĪ± nuclear receptors for anti-inflammatory gene transcription. Inhibits mast cell degranulation. Enhances endocannabinoid tone by inhibiting FAAH (increasing anandamide). Desensitizes TRPV1 pain channels via allosteric modulation. |
| Molecular weight | 318.13 Da (sodium salt) | 299.49 Da |
| Half-life | ~1-2 hours (plasma); tissue penetration lasts 12+ hours | ~1-2 hours (micronized form extends effects) |
| Bioavailability | ~6% systemic (topical); local tissue levels therapeutic | ~20% (standard); improved with micronized/ultra-micronized forms |
| Typical dose | 4g gel (1% or 2%) per joint | 300-1200 mg |
| Frequency | 3-4x daily | 2-3x daily |
| Route | Topical gel | Oral (micronized preferred) |
Diclofenac Topical reported benefits
- Localized pain relief
- Minimal systemic side effects
- Joint and tendon inflammation
- Post-workout recovery
- No GI ulcer risk
- OTC availability
PEA reported benefits
- Chronic pain reduction
- Neuropathic pain relief
- Anti-inflammatory (mast cell stabilization)
- No tolerance or dependence
- Neuroprotection
- Safe with other medications
Related comparisons
Research and educational reference only. Not medical advice.